Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 891 to 900 of 1514 total matches.

In Brief: Furoscix - A Subcutaneous Furosemide Infusor for Heart Failure

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2023  (Issue 1668)
/policies/drug-pricing-policy. The Medical Letter ® Vol. 65 (1668) January 23, 2023 Furoscix torsemide ...
The FDA has approved Furoscix (scPharmaceuticals), a subcutaneous formulation of the loop diuretic furosemide administered via a single-use, on-body infusor, for treatment of congestion due to fluid overload in adults with New York Heart Association (NYHA) Class II-III chronic heart failure (HF). Furosemide (Lasix, and generics) has been available for years in oral and IV formulations.
Med Lett Drugs Ther. 2023 Jan 23;65(1668):14-5   doi:10.58347/tml.2023.1668d |  Show IntroductionHide Introduction

In Brief: Rezvoglar - Another Insulin Glargine Product Interchangeable with Lantus

   
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023  (Issue 1673)
(AL, IN, SC, and WA) restrict interchangeability entirely.4 The Medical Letter ® Vol. 65 (1673 ...
Insulin glargine-aglr (Rezvoglar – Lilly), which was approved by the FDA as a biosimilar to the reference product Lantus in 2021 and received interchangeability status with Lantus in 2022, will become available in the US on April 1, 2023. It is the second biosimilar insulin product to be designated as interchangeable with Lantus; Semglee was the first. Rezvoglar did not receive interchangeability status with Lantus at the time of its initial approval because the manufacturer of Semglee had exclusivity for 12 months.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):56   doi:10.58347/tml.2023.1673c |  Show IntroductionHide Introduction

In Brief: Alternatives to Mifepristone for Medication Abortion

   
The Medical Letter on Drugs and Therapeutics • Jun 26, 2023  (Issue 1679)
duration of ≤63 days’ gestation, a regimen consisting of a single intramuscular The Medical Letter ® Vol ...
The possibility that use of mifepristone (Mifeprex, and generics) may be restricted has led to questions about alternatives for medication abortion.
Med Lett Drugs Ther. 2023 Jun 26;65(1679):102-3   doi:10.58347/tml.2023.1679d |  Show IntroductionHide Introduction

Empagliflozin (Jardiance) for Type 2 Diabetes in Children (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023  (Issue 1683)
® Vol. 65 Published online August 21, 2023 metformin Synjardy Victoza type 2 diabetes liraglutide ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin has been available for years alone (Jardiance – Boehringer Ingelheim) and in combination with metformin (Synjardy) to improve glycemic control in adults with type 2 diabetes. Both products have now been approved for use in children ≥10 years old. Empagliflozin is the second oral drug to become available in the US for treatment of type 2 diabetes in children; metformin has been available since 2000 for this indication. The injectable glucagon-like peptide-1 (GLP-1) receptor agonists liraglutide (Victoza) and...
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e137   doi:10.58347/tml.2023.1683e |  Show IntroductionHide Introduction

In Brief: Anktiva for Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
. All patients e106 The Medical Letter ® Vol. 66 Published online June 24, 2024 1. In brief: Adstiladrin ...
Nogapendekin alfa inbakicept-pmln (Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin)...
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-6   doi:10.58347/tml.2024.1705e |  Show IntroductionHide Introduction

Palonosetron (Aloxi) for Prevention of Nausea and Vomiting Due to Cancer Chemotherapy

   
The Medical Letter on Drugs and Therapeutics • Mar 29, 2004  (Issue 1179)
, New Rochelle, NY 10801 A Nonprofit Publication Vol. 46 (Issue 1179) March 29, 2004 Also ...
Palonosetron (Aloxi - Helsinn Healthcare SA, Switzerland, distributed in the US by MGI Pharma) is the fourth serotonin (5-HT3) receptor antagonist to become available in the US and the first to be approved by the FDA for prevention of both acute and delayed nausea and vomiting due to moderately emetogenic cancer chemotherapy. It is also approved for prevention of acute nausea and vomiting due to highly emetogenic drugs such as cisplatin (Platinol, and others). Aprepitant (Emend), a substance P/neurokinin-1 receptor antagonist, was approved last year for use with a 5-HT3 antagonist and...
Med Lett Drugs Ther. 2004 Mar 29;46(1179):27-8 |  Show IntroductionHide Introduction

Clobetasol Propionate (Clobex) Spray for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Mar 27, 2006  (Issue 1231)
March 27 Topical steroid topical steroids Treatment of psoriasis Ultravate Vanos vol 48 vol. 48 volume ...
The FDA has approved a new spray formulation of the super-high-potency corticosteroid clobetasol propionate 0.05% (Clobex - Galderma) for treatment of moderate to severe plaque psoriasis in adults. Clobetasol propionate is also available as a cream, ointment, gel, solution, foam, lotion and shampoo.
Med Lett Drugs Ther. 2006 Mar 27;48(1231):27-8 |  Show IntroductionHide Introduction

Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin

   
The Medical Letter on Drugs and Therapeutics • Apr 24, 2006  (Issue 1233)
volume 48 vol. 48 vol 48 type 2 diabetes type 1 diabetes rapid-acting insulin rapid acting insulin ...
Insulin glulisine (Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog). All three have a more rapid onset and shorter duration of action than regular human insulin. Rapid-acting insulin analogs are generally taken immediately before meals and are usually combined with a long-acting basal insulin.
Med Lett Drugs Ther. 2006 Apr 24;48(1233):33-4 |  Show IntroductionHide Introduction

Triumeq: A 3-Drug Combination for HIV

   
The Medical Letter on Drugs and Therapeutics • Jan 05, 2015  (Issue 1459)
to ...
The FDA has approved Triumeq (Viiv Healthcare), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir and the nucleoside reverse transcriptase inhibitors (NRTIs) abacavir and lamivudine, for once-daily treatment of HIV-1 infection. Dolutegravir (Tivicay) was approved as a single agent in 2013.
Med Lett Drugs Ther. 2015 Jan 5;57(1459):7-8 |  Show IntroductionHide Introduction

Extended-Release Hydrocodone (Hysingla ER) for Pain

   
The Medical Letter on Drugs and Therapeutics • May 11, 2015  (Issue 1468)
and will be available soon. 72 The Medical Letter ® Vol. 57 (1468) May 11, 2015 associated with sensorineural hearing ...
The FDA has approved a second extended-release (ER) formulation of the oral opioid agonist hydrocodone (Hysingla ER – Purdue) for management of pain severe enough to require continuous long-term therapy and for which alternative treatment options are inadequate. Hysingla ER tablets have abuse-deterrent properties to discourage their misuse.
Med Lett Drugs Ther. 2015 May 11;57(1468):71-2 |  Show IntroductionHide Introduction